Pharmaceutical Business review

ATMI unveils new bioreactor systems for cell-based products

The new range of bioreactors has been developed for fragile adherent cell culture applications on a large scale.

The Integrity bioreactors support safe and cost-efficient large-scale (large volume) production of traditional two-dimensional (2-D) cell cultures as it has cell culture parameter controls.

The 2-D multiplate design of the Xpansion bioreactors offers the same cell environment as standard multitray technology, besides providing the benefit of a closed system for increased protection from potential contamination.

ATMI LifeSciences cell culture technologies global director Jose Castillo said the Xpansion bioreactors represent a solution for process industrialization for cell therapies.

"Both patient safety and GMP compliance have been factored into the system’s design, as has operational simplicity," Castillo added.